前列腺12针系统穿刺在重复靶向穿刺中的应用价值研究  

The Research Application Value of 12-Core System Prostate Biopsy in Repeated Targeted Biopsy

作　　者：欧阳奎 蒋晓舻 杨睿[1] 袁贺佳 吴吉涛[1] 赵红伟[1] 

机构地区：[1]青岛大学附属烟台毓璜顶医院泌尿外科,山东 烟台

出　　处：《临床医学进展》2023年第3期4888-4892,共5页Advances in Clinical Medicine

摘　　要：目的:探讨重复前列腺穿刺中12针系统穿刺联合超声磁共振靶向融合穿刺的临床应用价值。方法:回顾性分析2019年6月~2021年9月烟台毓璜顶医院泌尿外科收治的既往活检阴性但PSA > 4 ng/ml患者的临床资料,进一步筛选出PI-RADS > 2分的患者。收集并比较患者前列腺系统穿刺和前列腺靶向穿刺的结果。结果:本研究共纳入211顺利完成穿刺的患者,穿刺针数为18.3 ± 3.1,共诊断出98 (46.4%)例前列腺癌组织,其中临床有意义前列腺癌组织69例(70.4%)。靶向穿刺检出前列腺癌72例(34.1%),临床有意义前列腺癌58例(80.6%),添加系统穿刺后,前列腺癌的检出率增加26例(12.3%, p < 0.001),临床有意义前列腺癌的检出人数增加11例(5.2%, p < 0.001)。结论:对于MRI提示可疑病灶的前列腺重复穿刺患者,靶向穿刺后添加系统穿刺能有效提高前列腺癌的检出率。Objective: To investigate the clinical application value of 12-core system biopsy combined with tar-geted fusion ultrasound magnetic resonance biopsy in repeated prostate biopsy. Methods: A retro-spective analysis of the clinical data of patients admitted to Yantai Yuhuangding Hospital of Urology between June 2019 and September 2021 with previous negative biopsy but PSA > 4 ng/ml was performed, and patients with PI-RADS > 2 points were further screened. The results of prostatic system biopsy and targeted prostatic biopsy were collected and compared. Results: A total of 211 patients who completed biopsy were included in this study, and the number of cores was 18.3 ± 3.1. A total of 98 (46.4%) cases of prostate cancer were diagnosed, including 69 (70.4%) cases of clini-cally significant prostate cancer. Targeted biopsy detected prostate cancer in 72 cases (34.1%) and clinically significant prostate cancer in 58 cases (80.6%). After systematic biopsy, the detection rate of prostate cancer increased by 26 cases (12.3%, p < 0.001), and clinically significant prostate can-cer was increased by 11 cases (5.2%, p < 0.001). Conclusion: For patients with repeated prostate biopsy indicated by MRI as suspicious lesions, systematic biopsy followed by targeted biopsy can effectively improve the detection rate of prostate cancer.

关 键 词：前列腺癌 前列腺穿刺术 经会阴 磁共振 前列腺特异性抗原 

分 类 号：R73[医药卫生—肿瘤]